Levetiracetam exhibits protective properties on rat Schwann cells in vitro

Journal of the Peripheral Nervous System

Volumn 16, Issue 3, 2011, Pages 250-260

  Stettner, Mark ^a   Dehmel, Thomas ^a   Mausberg, Anne K ^a   Köhne, Angelika ^a   Rose, Christine R ^b   Kieseier, Bernd C ^a  

^a Department of Neurology   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

dorsal root ganglia; histone deacetylase inhibitors; levetiracetam; matrix metalloproteinases; Schwann cell

Indexed keywords

CALCIUM; CASPASE 6; ETIRACETAM; GELATINASE A; GELATINASE B; GLUTAMIC ACID; LIPOPOLYSACCHARIDE; SODIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; MYELINATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SCHWANN CELL; SODIUM CELL LEVEL; SPINAL GANGLION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; CELLS, CULTURED; GLUTAMIC ACID; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PIRACETAM; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SCHWANN CELLS;

EID: 80054990142     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00355.x     Document Type: Article

References (43)

1. Abbas A, Gupta S, (2008). The role of histone deacetylases in prostate cancer. Epigenetics 3: 300-309.
2. Abou-Khalil B, (2008). Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 4: 507-523. (Pubitemid 352037830)
3. Askwith T, Zeng W, Eggo MC, Stevens MJ, (2009). Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy. Am J Physiol Endocrinol Metab 297: E620-E628.
4. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Brockes JP, Fields KL, Raff MC, (1979). Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 165: 105-118. (Pubitemid 9148699)
6. Brownlee M, (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820. (Pubitemid 34000785)
7. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E, (1995). Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201: 223-226. (Pubitemid 26009985)
8. Chattopadhyay S, Myers RR, Janes J, Shubayev V, (2007). Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav Immun 21: 561-568. (Pubitemid 46829772)
9. Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC, (2007). The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis 25: 665-674.
10. Dogonadze SI, Ninua NG, Gordeziani MG, Kavlashvili MS, Sanikidze TV, (2006). The role of oxidative stress in pathogenesis of GBS. Georgian Med News 140: 43-47.
11. Eldridge CF, Bunge MB, Bunge RP, (1989). Differentiation of axon-related Schwann cells in vitro: II. Control of myelin formation by basal lamina. J Neurosci 9: 625-638. (Pubitemid 19069507)
12. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M, (2004). The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45: 737-744. (Pubitemid 38890970)
13. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV, (1992). Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 40: 197-210.
14. Herzog RI, Liu C, Waxman SG, Cummins TR, (2003). Calmodulin binds to the C terminus of sodium channels Nav1.4 and Nav1.6 and differentially modulates their functional properties. J Neurosci 23: 8261-8270. (Pubitemid 37129643)
15. Jangouk P, Dehmel T, Meyer Zu, Horste G, Ludwig A, Lehmann HC, Kieseier BC, (2009). Involvement of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. Glia 57: 1765-1774.
16. Kelly T, Rose C, (2010). Ammonium influx pathways into astrocytes and neurones of hippocampal slices. J Neurochem 115: 1123-1136.
17. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, Gearing AJ, Hartung HP, (1998). Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121: 159-166. (Pubitemid 28045514)
18. Kobayashi H, Chattopadhyay S, Kato K, Dolkas J, Kikuchi S, Myers RR, Shubayev VI, (2008). MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 39: 619-627.
19. Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HW, Frick R, Muljana L, Piek J, Yonekawa Y, Gaab MR, (2000). Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 23: 145-150.
20. Lehmann HC, Kohne A, Meyer zu Horste G, Dehmel T, Kiehl O, Hartung HP, Kastenbauer S, Kieseier BC, (2007). Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies. J Neuropathol Exp Neurol 66: 305-312. (Pubitemid 46559023)
21. Lehmann HC, Kohne A, Bernal F, Jangouk P, Meyer Zu, Horste G, Dehmel T, Hartung HP, Previtali SC, Kieseier BC, (2009). Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons. Glia 57: 479-489.
22. Lo AC, Black JA, Waxman SG, (2002). Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 13: 1909-1912. (Pubitemid 35398958)
23. Lo AC, Saab CY, Black JA, Waxman SG, (2003). Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90: 3566-3571. (Pubitemid 37430046)
24. Lukyanetz EA, Shkryl VM, Kostyuk PG, (2002). Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43: 9-18. (Pubitemid 34215447)
25. Mai A, Rotili D, Valente S, Kazantsev AG, (2009). Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 15: 3940-3957.
26. McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM, (2005). Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 280: 6561-6569. (Pubitemid 40341206)
27. Meyer zu Horste G, Hu W, Hartung HP, Lehmann HC, Kieseier BC, (2008). The immunocompetence of Schwann cells. Muscle Nerve 37: 3-13.
28. Nakashima E, Pop-Busui R, Towns R, Thomas TP, Hosaka Y, Nakamura J, Greene DA, Killen PD, Schroeder J, Larkin DD, Ho YL, Stevens MJ, (2005). Regulation of the human taurine transporter by oxidative stress in retinal pigment epithelial cells stably transformed to overexpress aldose reductase. Antioxid Redox Signal 7: 1530-1542. (Pubitemid 41767989)
29. Nave KA, (2010). Myelination and the trophic support of long axons. Nat Rev Neurosci 11: 275-283.
30. Passmore GM, (2005). Dorsal root ganglion neurones in culture: a model system for identifying novel analgesic targets? J Pharmacol Toxicol Methods 51: 201-208. (Pubitemid 40615600)
31. Podratz JL, Rodriguez E, Windebank AJ, (2001). Role of the extracellular matrix in myelination of peripheral nerve. Glia 35: 35-40. (Pubitemid 32656751)
32. Redford EJ, Smith KJ, Gregson NA, Davies M, Hughes P, Gearing AJ, Miller K, Hughes RA, (1997). A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 120: 1895-1905. (Pubitemid 27443062)
33. Rogawski MA, (2006). Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69: 273-294. (Pubitemid 44209049)
34. Rose CR, Ransom BR, (1996). Intracellular sodium homeostasis in rat hippocampal astrocytes. J Physiol 491: 291-305. (Pubitemid 26078961)
35. Rosenberg GA, (2002). Matrix metalloproteinases in neuroinflammation. Glia 39: 279-291.
36. Schneble H, (2006). Pharmakotherapie der Epilepsien. Deutsche Sektion der internationalen Liga gegen Epilepsie, Kehl-Kork.
37. Shubayev VI, Angert M, Dolkas J, Campana WM, Palenscar K, Myers RR, (2006). TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol Cell Neurosci 31: 407-415. (Pubitemid 43358015)
38. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, Thelen P, (2007). The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6: 2626-2633. (Pubitemid 350058143)
39. Tilleux S, Hermans E, (2007). Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 85: 2059-2070. (Pubitemid 47172138)
40. Waxman SG, (2008). Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 4: 159-169. (Pubitemid 351356596)
41. Yang XJ, (2004). Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 26: 1076-1087.
42. Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A, Endres M, (2008). Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 210: 531-542.
43. Zapater P, Moreno J, Horga JF, (1997). Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res 772: 57-62. (Pubitemid 27501683)